These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33073005)

  • 1. Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Int J Neonatal Screen; 2020 Mar; 6(1):6. PubMed ID: 33073005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing steroid profiling by liquid chromatography-tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Clin Endocrinol (Oxf); 2021 Jun; 94(6):904-912. PubMed ID: 33471388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
    de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a New Laboratory Protocol for Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand.
    de Hora MR; Heather NL; Webster DR; Albert BB; Hofman PL
    Int J Neonatal Screen; 2022 Oct; 8(4):. PubMed ID: 36278626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
    Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
    Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives.
    de Hora M; Heather N; Webster D; Albert B; Hofman P
    Front Endocrinol (Lausanne); 2023; 14():1226284. PubMed ID: 37850096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.
    Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test.
    Cavarzere P; Camilot M; Palma L; Lauriola S; Gaudino R; Vincenzi M; Antoniazzi F; Teofoli F; Piacentini G
    Horm Res Paediatr; 2022; 95(3):255-263. PubMed ID: 35350013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme.
    Lai F; Srinivasan S; Wiley V
    Int J Neonatal Screen; 2020 Sep; 6(3):63. PubMed ID: 33117905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
    Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia.
    Conlon TA; Hawkes CP; Brady JJ; Loeber JG; Murphy N
    Horm Res Paediatr; 2024; 97(2):113-125. PubMed ID: 37231960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of 17 α-hydroxyprogesterone in bloodspots by liquid chromatography tandem mass spectrometry.
    Salter SJ; Cook P; Davies JH; Armston AE
    Ann Clin Biochem; 2015 Jan; 52(Pt 1):126-34. PubMed ID: 24842631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Screening for Congenital Adrenal Hyperplasia in Denmark: 10 Years of Experience.
    Lind-Holst M; Bækvad-Hansen M; Berglund A; Cohen AS; Melgaard L; Skogstrand K; Duno M; Main KM; Hougaard DM; Gravholt CH; Hansen D
    Horm Res Paediatr; 2022; 95(1):35-42. PubMed ID: 35114680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry.
    Lacey JM; Minutti CZ; Magera MJ; Tauscher AL; Casetta B; McCann M; Lymp J; Hahn SH; Rinaldo P; Matern D
    Clin Chem; 2004 Mar; 50(3):621-5. PubMed ID: 14656905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.
    Monostori P; Szabó P; Marginean O; Bereczki C; Karg E
    Horm Res Paediatr; 2015; 84(5):311-8. PubMed ID: 26397944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal screening for congenital adrenal hyperplasia.
    White PC
    Nat Rev Endocrinol; 2009 Sep; 5(9):490-8. PubMed ID: 19690561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
    Fingerhut R
    Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from 28 years of newborn screening for congenital adrenal hyperplasia in sapporo.
    Morikawa S; Nakamura A; Fujikura K; Fukushi M; Hotsubo T; Miyata J; Ishizu K; Tajima T
    Clin Pediatr Endocrinol; 2014 Apr; 23(2):35-43. PubMed ID: 24790385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.